Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-22

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ischemic digital ulcers (DUs) are a frequent complication in systemic sclerosis with a major impact on hand function and quality of life. Digital injection of cultured adipose-derived stromal cell (AdMSC) constitutes a promising approach to treat scleroderma-induced refractory ischemic DUs where no alternative therapy is validated. The aim of this phase 2 study is to compare efficacy and safety of digital injection of AdMSC versus placebo for healing refractory active ischemic digital ulcers in patients with systemic sclerosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by an autoimmune-mediated microangiopathy and progressive fibrosis. Ischemic digital ulcers (DUs) are frequent in the disease course. DUs are an expression of the severity of the microangiopathy. DUs lead to pain, infection, gangrene, autoamputation, impaired hand use and impaired quality of life. The management of DUs is often based on optimal wound care to promote healing and and repeated hospitalizations to perform onerous prostacyclin infusions to reduce pain and accelerate healing. With optimal standard of care, only 60% of DUs are healed after 3 months and 46.2% experiences recurrence during that time among them 11.2% experiences a chronic evolution. No drug has demonstrated a positive effect on refractory DUs healing. The rational underlying the use of cultured adipose-derived stromal cell (AdMSC) in this indication is based on the finding of AdMSC, in vitro and in vivo, angiogenic and anti-inflammatory potential in other ischemic pathologies, with an excellent safety profile. The pilot phase of the ACellDREAM trial demonstrated the feasibility and safety of AdMSC transplantation in patients with non- revascularizable critical limb ischemia and showed improvement in ulcer evolution and wound healing. The EFS-O culture procedure safety is validated and is already in use in ongoing French and European clinical trials. Two pilot studies showed the safety of adipose tissue grafting for scleroderma-Induced DU. The SCLERADEC pilot study outlines the safety, in 12 SSc patients, of the digital injection of adipose- derived stromal vascular fraction, which is a heterogeneous population of cells including only 36% of uncultured AdMSC. An improvement in hand disability, quality of life and DUs was observed, the phase II is ongoing. The hypothesis of the study is that digital injection of AdMSC could be efficacious for scleroderma-induced refractory ischemic DUs healing by digital vascular regeneration in a clinical situation where no alternative therapy is validated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AdMSC

Subcutaneous injections of cultured adipose-derived stroma/stem cells to heal refractory ischemic digital ulcers in patients with scleroderma

Group Type EXPERIMENTAL

AdMSC

Intervention Type DRUG

At day 0, patients will have AdMSC injections in their ischemic DU. Patients will be followed-up for 16 weeks

Placebo

Subcutaneous injections of placebo comparator to heal refractory ischemic digital ulcers in patients with scleroderma

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

At day 0, patients will have placebo injections in their ischemic DU. Patients will be followed-up for 16 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AdMSC

At day 0, patients will have AdMSC injections in their ischemic DU. Patients will be followed-up for 16 weeks

Intervention Type DRUG

Placebo

At day 0, patients will have placebo injections in their ischemic DU. Patients will be followed-up for 16 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patient ≥18 years of age,
* Patient with systemic sclerosis according to the 2013 ACR/EULAR classification criteria9,
* SSc patient with at least one refractory active ischemic digital ulcer at "inclusion visit" (see below the eligibility conditions of a DU),
* Age \> 50 years and not treated with any kind of hormone replacement therapy for at least 2 years prior to screening, with amenorrhea for at least 24 consecutive months prior to screening. An assessment of serum follicle stimulating hormone showing a level of \> 40 TU/L at screening may be used to exclude childbearing potential, based on the discretion of the investigator,
* Patient must have provided written informed consent prior to enrolment,
* Patient must be able to understand their requirements of participating in the protocol,
* Patient affiliated to a social security system.
* Relative to each DU :

The DU at " inclusion visit " must show all the following characteristics:

1. Located beyond the proximal interphalangeal joint, on finger surface (included periungual ulcers),
2. Of ischemic origin according to the physician,
3. Not over subcutaneous calcifications or bone relief,
4. Active DU,
5. Refractory after 10±2 weeks of standard of care according to EULAR recommendations26 (that is either still active (chronic) or new occurrence despite standard of care)

Exclusion Criteria

* Current smoker or tobacco consumption stopped for less than 3 months prior to inclusion, - Patient participating in a clinical trial or having participated in a clinical trial within the previous 3 months,
* Patients on statins, who have received treatment for less than 3 months prior to Screening or whose treatment has not been stable during this period,
* Patients on vasodilators, such as endothelin receptor antagonists (ERAs), PDE5 inhibitors (e.g. sildenafil, tadalafil), calcium channel blockers, ACE-inhibitors, nitroglycerin, alpha adrenergic blockers, or angiotensin II receptor antagonists, N-acetylcysteine, antiplatelet aggregation therapy and low molecular weight heparin who have received treatment if present for less than 3 months prior to "inclusion visit" or whose treatment has not been stable for at least 1 month prior to "inclusion visit",
* Treatment with disease modifying agents such as methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, Interferons and cyclophosphamide, those drugs should be stop at least 1 month prior study entry.
* Treatment with oral corticosteroids (\> 10 mg/day of prednisone or equivalent),
* Systemic antibiotics (oral and TV) to treat infected DU(s) within 4 weeks prior to "inclusion visit",
* Use of topical growth factors, hyperbaric oxygen,
* Local injection of botulinum toxin in an affected finger within 4 weeks prior to "inclusion visit",
* Surgical sympathectomy of the upper limbs or surgical wound debridement within 1 month prior to "inclusion visit",
* Liposuction technically impossible,
* Patient who underwent autologous hematopoietic stem cell transplantation (HSCT) within less than 1 year,
* Patients with an indication for intensification by autologous HSCT (according to EBMT guidelines and national RCP MATHEC),
* History of cancer in the last five years, except for successfully excised basal cell/squamous cell carcinoma, or successfully excised early melanoma of the skin. Subjects, who had successfully tumor resection or radiation or chemotherapy more than 5 years from inclusion and no recurrence, may be enrolled in the study, - Subjects who have active proliferative retinopathy,
* Positive HIV-1 or 2, HTLV-1 or 2, HBV or HCV,
* Patients with a history of stroke, myocardial infarction or severe arrhythmia in the last 6 months
* Patient who had severe cardiac failure in the last 6 months,
* Females who are pregnant or breastfeeding or plan to do so during the course of this study,
* Patient under judicial protection, - Refusal of the patient to participate in the study.
* Relative to each DU:

1. Digital ulcer due to conditions other than scleroderma,
2. Non ischemic digital ulcer,
3. Ulcers with osteomyelitis, or clinically uncontrolled infection,
4. Infected digital ulcer requiring systemic antibiotherapy,
5. Digital ulcer requiring urgent surgery.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Grégory PUGNET, MD, PHD

Role: PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.